ATAI is a biotechnology company founded in 2018 in response to the clear and growing unmet needs of mental health patients worldwide. atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. ATAI’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential.
ATAI now has multiple new medical drugs in the pipeline in various stages. Learn more about them all and their value here.
|Name||ATAI Life Sciences|